Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report)’s share price dropped 9% on Wednesday. The stock traded as low as $0.8535 and last traded at $0.8535. Approximately 100 shares were traded during trading, a decline of 100% from the average session volume of 22,464 shares. The stock had previously closed at $0.9376.
Avacta Group Price Performance
The company has a 50 day moving average of $0.94 and a 200 day moving average of $0.96.
Avacta Group Company Profile
Avacta Group plc is a United Kingdom-based life sciences company focused on developing targeted cancer treatments. Its principal technology platform, pre|CISION, is designed to activate medicines selectively within the tumor microenvironment, with the goal of improving treatment effectiveness while reducing exposure to healthy tissue.
The company’s lead clinical program is AVA6000, a tumor-activated form of doxorubicin being investigated for the treatment of solid tumors, including soft-tissue sarcoma.
Featured Stories
- Five stocks we like better than Avacta Group
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
